Berkeley Heights, NJ - October 31, 2005-
Conference call information:
US/Canada call: 877-634-8606; conference code 1604361
International call: 706-679-3140; conference code 1604361
Webcast:
http://www.genta.com/genta/InvestorRelation/events.html
Audio replay will be available approximately two hours after the
completion of the call and will be archived for 30 days.
About Genta
Genta Incorporated is a pharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with
cancer. The Company's research platform is anchored by two
major programs that center on oligonucleotides (RNA- and DNA-based
medicines) and small molecules. Genasense® (oblimersen
sodium) Injection, the Company's lead compound from its
oligonucleotide program, is currently undergoing late-stage, Phase
3 clinical testing. In 2005, the Company initiated a
"rolling" New Drug Application to the Food and Drug Administration
for the use of Genasense plus fludarabine and cyclophosphamide in
patients with relapsed or refractory chronic lymphocytic
leukemia. The Company has also indicated its intention to
submit in 2005 a Marketing Authorization Application (MAA) to the
European Medicines Agency (EMEA) for the use of Genasense plus
dacarbazine in patients with advanced melanoma. The leading
drug in Genta's small molecule program is Ganite® (gallium nitrate
injection), which the Company is exclusively marketing in the U.S.
for treatment of patients with cancer related hypercalcemia that is
resistant to hydration. For more information about Genta,
please visit our website at: www.genta.com.
This press release contains forward-looking statements with
respect to business conducted by Genta Incorporated. By
their nature, forward-looking statements and forecasts involve
risks and uncertainties because they relate to events and depend
on circumstances that will occur in the future. There are a
number of factors that could cause actual results and
developments to differ materially. For a discussion of
those risks and uncertainties, please see the Company's Annual
Report/Form 10-K for 2004.
